Frontiers in Endocrinology最新文献

{"title":"Editorial: Long-acting growth hormone therapy in pediatric growth hormone deficiency.","authors":"Anastasia Ibba, Giuseppa Patti, Sandro Loche","doi":"10.3389/fendo.2026.2005952","DOIUrl":"https://doi.org/10.3389/fendo.2026.2005952","url":null,"abstract":"","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"2005952"},"PeriodicalIF":5.7,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13686851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149265161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-scale genetic, molecular, and cellular triangulation prioritizes <i>ACSL5</i> as a T3-responsive candidate linking hypothyroidism liability to anemia.","authors":"Hui Li, Tao Jiang, Huan Wang, Mei Wang, Sixi Xie","doi":"10.3389/fendo.2026.1943954","DOIUrl":"https://doi.org/10.3389/fendo.2026.1943954","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Anemia is a recognized complication of hypothyroidism, but disease-level genetic studies have not identified a clear erythroid cell-intrinsic target. We integrated genetic validation, molecular-QTL prioritization, and replicated triiodothyronine (T3)-responsive erythroid experiments to identify candidates linking hypothyroidism liability to anemia.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;Two-sample Mendelian randomization (MR) assessed genetically predicted hypothyroidism and anemia. Source metadata were reviewed for possible sample overlap, and two cross-biobank forward validations were performed. Strict reverse MR used the original OpenGWAS identifiers; because anemia provided no genome-wide-significant instruments, a &lt;i&gt;post hoc&lt;/i&gt; analysis used &lt;i&gt;p&lt;/i&gt; &lt; 5 × 10&lt;sup&gt;-6&lt;/sup&gt;. Non-major histocompatibility complex (MHC) methylation summary-based Mendelian randomization (SMR) and whole-blood expression SMR were integrated, followed by a public fine-mapping/colocalization lookup for two acyl-CoA synthetase long-chain family member 5 (&lt;i&gt;ACSL5&lt;/i&gt;) cytosine-phosphate-guanine (CpG) sites and the &lt;i&gt;ACSL5&lt;/i&gt; eQTL. &lt;i&gt;ACSL5&lt;/i&gt; was examined in three independent hemin-induced K562, a human chronic myelogenous leukemia cell line experiments with or without T3; Triacsin C and oleic acid-bovine serum albumin (BSA) served as pathway-level perturbations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Primary inverse-variance weighted (IVW) analysis associated hypothyroidism liability with higher anemia odds (OR = 1.0304; 95% CI, 1.0195-1.0414; &lt;i&gt;p&lt;/i&gt; = 3.42 × 10&lt;sup&gt;-8&lt;/sup&gt;). Both primary genome-wide association studies (GWASs) were UK Biobank-derived, and their exact participant overlap could not be determined from public summary-level information. A participant-independent FinnGen hypothyroidism-to-UK Biobank anemia validation reproduced the positive direction (28 instruments; IVW beta = 0.001448, &lt;i&gt;p&lt;/i&gt; = 4.14 × 10&lt;sup&gt;-4&lt;/sup&gt;); the complementary UK Biobank hypothyroidism-to-FinnGen anemia analysis was also positive. Strict original-ID reverse MR was not estimable; the exploratory eight-instrument analysis was null and heterogeneous. Six non-MHC CpGs passed Bonferroni correction, including two mapped to &lt;i&gt;ACSL5&lt;/i&gt;, while whole-blood &lt;i&gt;ACSL5&lt;/i&gt; expression showed an inverse SMR estimate. The public lookup returned no pairwise CpG-expression colocalization. In all three K562 experiments, hemin plus T3 increased &lt;i&gt;HBA1&lt;/i&gt;, &lt;i&gt;HBA2&lt;/i&gt;, &lt;i&gt;GYPA&lt;/i&gt;, and &lt;i&gt;ACSL5&lt;/i&gt; expression. Triacsin C suppressed erythroid-marker expression, whereas oleic acid-BSA produced a partial increase without exogenous T3.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Cross-scale evidence prioritizes &lt;i&gt;ACSL5&lt;/i&gt; as a T3-responsive candidate linking hypothyroidism liability to anemia and implicates long-chain fatty-acid handling as a research direction. However, negative CpG-expression colocalization and nongene-specific pharmacological interventions preclude","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1943954"},"PeriodicalIF":5.7,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13686861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149265117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of significant weight loss following bariatric surgery on the differential expression of phosphopeptides in human seminal fluid.","authors":"Sally F Vitez, Odei Barreñada, Kathleen Hwang, Miguel Angel Brieño-Enríquez","doi":"10.3389/fendo.2026.1907857","DOIUrl":"https://doi.org/10.3389/fendo.2026.1907857","url":null,"abstract":"<p><p>During the last few decades, the global population has shown increased obesity rates. Obesity has been linked to declines in male reproductive capacity, suggesting a causal connection. However, standard fertility tests, such as semen analysis, often fail to predict reproductive success accurately because they do not assess molecular and functional sperm qualities. To address this, this pilot study explores the role of post-translational modifications, such as phosphorylation, as potential fertility markers. We studied six morbidly obese men scheduled for bariatric surgery; all of them were monitored before surgery and then 3 and 6 months afterward. Recruited patients showed statistically significant weight loss and improved hormonal profiles, including higher testosterone and SHBG levels; however, standard semen parameters changed little. Using Mass spectrometry, we evaluated the sperm proteome and phosphoproteome from control patients and patients before and 3 and 6 months after bariatric surgery. Sperm proteomics showed no differences across collection times; however, phosphoproteomics of seminal fluid revealed that 7 phosphopeptides differed significantly across collection times. These post-translational modifications were observed in proteins such as semenogelin-1, semenogelin-2, mucin-6, and AKAP-3 and AKAP-4. Interestingly, these proteins are critical in sperm capacitation, a vital process for fertilization, suggesting a potential molecular mechanism for the reduced reproductive function in obese patients. These results suggest that seminal fluid, rather than sperm alone, may be crucial in mediating changes in fertility associated with obesity and weight loss. Although our results come from a small patient population, the findings highlight the shortcomings of conventional semen analysis and support the potential use of proteomic biomarkers to better understand and assess male fertility amid obesity and metabolic changes.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1907857"},"PeriodicalIF":5.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13684861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progesterone levels on hCG trigger day and neonatal outcomes in fresh embryo transfers: a retrospective threshold analysis of GnRH antagonist versus agonist long protocols.","authors":"Jing Wu, Hengde Zhang, Jianlei Huang, Li Hai, Xinxin Liang, Dan Liu, Jing Zhou, Xuan Li, Yuping He, Xiaohong Wang","doi":"10.3389/fendo.2026.1982427","DOIUrl":"10.3389/fendo.2026.1982427","url":null,"abstract":"<p><strong>Background: </strong>Elevated progesterone levels on the day of human chorionic gonadotropin (hCG) trigger are known to adversely affect pregnancy outcomes in fresh embryo transfer (fET) cycles, but their impact on neonatal outcomes remains poorly understood. This study aimed to investigate the association between progesterone levels on hCG trigger day and neonatal outcomes, and to explore the progesterone threshold, so as to provide reference for clinical decision-making.</p><p><strong>Methods: </strong>This retrospective cohort study included 2, 201 patients who achieved singleton live births following fET between April 1, 2021 and December 31, 2024. All patients were ≤ 42 years of age and underwent either a GnRH antagonist protocol or an agonist long protocol. A multivariable regression analysis was performed to detect the relationship between progesterone level and neonatal outcomes. Smooth curve fitting and threshold effect analysis were used to evaluate the cutoff value of progesterone level.</p><p><strong>Results: </strong>In the overall population, higher progesterone levels were significantly associated with increased risks of preterm delivery (PTD) (adjusted OR: 1.89, 95% CI: 1.03 to 3.47, P = 0.0399) and low birthweight (LBW) (adjusted OR: 2.67, 95% CI: 1.14 to 6.24, P = 0.0231). These associations were observed only in the GnRH antagonist protocol, particularly with progesterone ≥ 1.0 ng/mL significantly elevating the risks of PTD (adjusted OR: 4.54, 95% CI: 2.16 to 9.56, P = 0.0021) and LBW (adjusted OR: 4.16, 95% CI: 1.15 to 15.07, P = 0.0378). Threshold analysis further identified progesterone > 0.90 ng/mL as the inflection point for PTD (adjusted OR: 6.60, 95% CI: 2.52 to 14.56, P = 0.0131) and progesterone > 0.98 ng/mL for LBW (adjusted OR: 7.50, 95% CI: 3.71 to 15.87, P = 0.0038) in antagonist cycles. No such associations were found in the GnRH agonist long protocol.</p><p><strong>Conclusions: </strong>Our findings suggest that in GnRH antagonist cycles, a serum progesterone level exceeding 0.90 ng/mL on hCG trigger day may serve as an independent predictor of an increased risk of PTD in singletons born after fET. These results highlight the need for enhanced perinatal surveillance in this population, and call for further validation in larger prospective multicenter studies.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1982427"},"PeriodicalIF":5.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capsaicin ameliorates diabetic nephropathy by targeted activation of GPX4 and inhibition of pyroptosis.","authors":"Congqin Zhang, Xiaorong Wang, Fang Zhang, Chunhui Li, Xue Zhao, Sinan Zhao, Jing Liu, Sumin Jiao, Yongmei Hao","doi":"10.3389/fendo.2026.1937280","DOIUrl":"10.3389/fendo.2026.1937280","url":null,"abstract":"<p><strong>Purpose: </strong>Capsaicin (CAP) is the primary pungent alkaloid found in chili peppers. The aim of this study is to screen for candidate therapeutic agents targeting the mitochondrial dysfunction-pyroptosis axis in diabetic nephropathy (DN) and to validate the efficacy and mechanism of action of capsaicin.</p><p><strong>Methods: </strong>Bioinformatics analysis was conducted to identify candidate genes and drugs. The protective effects and underlying mechanisms of CAP were investigated using a high-glucose (HG)-induced HK-2 cell model and a streptozotocin-induced T1DM DN rat model. Experimental techniques included CCK8 assay, flow cytometry (pyroptosis and ROS), JC-1 staining, Western blot analysis, and histopathological staining. GPX4-IN-3 was applied <i>in vivo</i> and <i>in vitro</i> to determine whether it reversed the protective effects of capsaicin. The data were analyzed using the Shapiro-Wilk test, one-way analysis of variance (ANOVA) with corresponding post-hoc tests, and correlation analysis.</p><p><strong>Results: </strong>Bioinformatic analysis identified 12 intersecting genes and highlighted CAP as a potential GPX4-targeting compound. Molecular docking demonstrated a high binding affinity of CAP for GPX4 and caspase-9. <i>In vitro</i>, CAP dose-dependently restored cell viability and suppressed HG-induced pyroptosis in HK-2 cells. It significantly alleviated mitochondrial damage by reducing ROS production, restoring mitochondrial membrane potential, and improving mitochondrial ultrastructure. Notably, these protective effects were reversed by GPX4-IN-3. Western blot analysis revealed that CAP upregulated GPX4 expression and inhibited activation of the NLRP3/caspase-1/GSDMD-N pyroptosis pathway. <i>In vivo</i>, CAP treatment markedly improved renal histopathology and renal function in DN rats; however, these effects were attenuated by co-administration of GPX4-IN-3.</p><p><strong>Conclusion: </strong>This study demonstrates that CAP ameliorates diabetic renal injury by targeting GPX4, thereby mitigating mitochondrial dysfunction and subsequent NLRP3-mediated pyroptosis. These findings validate the bioinformatic prediction and reveal a novel mechanism of action for CAP, positioning it as a promising therapeutic candidate for DN.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1937280"},"PeriodicalIF":5.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between symptoms of adenomyosis and current ultrasonographic diagnostic criteria.","authors":"Sofia Ivanisevic, E Shirin Dason, Christina Hanna, Emma Rebecca Evelyn Sparks, Stella Wang, Ella Huszti, Rebecca Ngu, Alexander Hartman, Mara Sobel","doi":"10.3389/fendo.2026.1924781","DOIUrl":"10.3389/fendo.2026.1924781","url":null,"abstract":"<p><strong>Introduction: </strong>Adenomyosis is a uterine disorder defined by presence of endometrial glands and stroma within the myometrium with surrounding myometrial hyperplasia. Research has shown that ultrasound (US) can play a key role in early adenomyosis diagnosis and treatment. The Morphological Uterus Sonographic Assessment (MUSA) recently published standardized criteria for ultrasonographic diagnosis of adenomyosis, but the relationship between these criteria and clinical symptoms, has yet to be clinically validated.</p><p><strong>Objectives: </strong>To assess the prevalence of MUSA ultrasound criteria of adenomyosis and relationship between rates of ultrasound features and clinical symptoms of adenomyosis.</p><p><strong>Methods: </strong>This is an analytical cross-sectional study of patients aged 18-52 receiving a transvaginal ultrasound for any indication at a single outpatient imaging center. Patients were excluded if they had a hysterectomy and/or bilateral oophorectomy, were in menopause, or had active gynecologic malignancy. Patients completed a survey to assess for infertility or fertility-related healthcare use, heavy menstrual bleeding, and pelvic pain. Ultrasound images were assessed by a radiologist using MUSA criteria to evaluate for adenomyosis. Multivariate analyses assessed association between MUSA features and patient-reported symptoms.</p><p><strong>Results: </strong>Of 271 recruited participants, 11.4% had at least one direct feature of adenomyosis, 57.6% had no direct features but at least one indirect feature, and 31.0% had no features. After controlling for potential confounders in multivariable analysis, patients with direct features resulted in 5.955-point higher heavy bleeding scores compared to those with no features (95% CI 1.970-9.939, p=0.004). When controlling for covariates, the association between indirect features and adenomyosis symptoms were not significant. Subjects with middle myometrium invasion reported increased rates of infertility (p=0.006), whereas subjects with outer myometrial involvement reported significantly higher heavy bleeding (p=0.002).</p><p><strong>Conclusions: </strong>Per MUSA criteria, 1 in 10 participants displayed ultrasonographic findings strongly suggestive of presence of adenomyosis. Patients with direct features were more likely to experience heavy menstrual bleeding. Layer of uterine involvement were found to have greater association with infertility and pelvic pain than any one MUSA feature.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1924781"},"PeriodicalIF":5.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified fasting therapy reduces blood pressure independent of weight loss, moderated by age, sex, and HbA1c: a retrospective mediation analysis in dysglycemic patients.","authors":"Ziheng Ye, Jiapan Sun, Tingying Zhang, Jiahao Feng, Dongkai Zeng, Yidan Qin, Li Zhang, Jian Qin, Taoli Liu","doi":"10.3389/fendo.2026.1976220","DOIUrl":"10.3389/fendo.2026.1976220","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of modified fasting therapy on blood pressure in dysglycemic adults and to examine the mediating role of weight loss and modifying effects of age, sex, and baseline glycemic status.</p><p><strong>Methods: </strong>This retrospective cohort study included 833 dysglycemic adults who underwent modified fasting therapy. Blood pressure, body weight, and laboratory parameters were measured before and after the intervention. Linear mixed models were used to estimate the effect of fasting on systolic blood pressure (SBP) and diastolic blood pressure (DBP), with adjustment for age, sex, baseline body mass index (BMI), glycosylated hemoglobin (HbA1c), and baseline blood pressure. Mediation analyses were performed using \"MEMORE macro\" and \"wsMed\" package to examine the mediating role of weight loss. Interaction terms were included to test effect modification by age, sex, and baseline HbA1c.</p><p><strong>Results: </strong>Fasting therapy significantly reduced SBP (-7.73 mmHg, 95% CI: -8.64 to -6.82, <i>p</i> < 0.001) and DBP (-4.76 mmHg, 95% CI: -5.39 to -4.12, <i>p</i> < 0.001). Mediation analyses revealed that weight loss did not significantly mediate the blood pressure-lowering effect for either SBP (indirect effect: -0.22, <i>p</i> = 0.588) or DBP (indirect effect: 0.09, <i>p</i> = 0.636). The fasting effect was significantly modified by age, sex, and baseline HbA1c, with greater reductions observed in younger patients, males, and those with higher HbA1c levels.</p><p><strong>Conclusions: </strong>Modified fasting therapy significantly reduces blood pressure in dysglycemic adults independent of weight loss. Age, sex, and baseline HbA1c modify the response, suggesting that personalized approaches may optimize the benefits of fasting-based interventions.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1976220"},"PeriodicalIF":5.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The comparison between short-term fertilization and conventional fertilization in <i>in vitro</i> fertilization treatment: a propensity score matching study.","authors":"Dong Han, Xueying Kong, Jie Liu, Yan Zhou, Shiping Chen, Xiaomiao Zhao, Caixia Liu, Chaofan Zhang","doi":"10.3389/fendo.2026.1801741","DOIUrl":"10.3389/fendo.2026.1801741","url":null,"abstract":"<p><p>Short-term IVF (S-IVF) is a fertilization approach to co-incubate the sperm and oocyte for a short duration and denude the cumulus cells afterwards. The S-IVF combined with early rescue intracytoplasmic sperm injection (ICSI) strategy can reduce the occurrence of both total fertilization failure (TFF) and the lower fertilization rate (<30%). However, there is still no consensus regarding the use of S-IVF. This study aimed to compare short-term <i>in vitro</i> fertilization (S-IVF) with conventional <i>in vitro</i> fertilization (C-IVF) in terms of fertilization, embryo developmental potential, and clinical outcomes. We used propensity score matching (PSM) to construct a 1:5 cohort of S-IVF and C-IVF cycles and compared fertilization, embryo developmental potential, and clinical outcomes between the two groups. We screened 68 S-IVF and 340 C-IVF patients (each in their first ART cycle-so cycle and patient numbers are identical) by baseline characteristics. The primary outcome was the fertilization rate, and the secondary outcomes were the pregnancy rate and abortion rate in cohort. The results showed that the C-IVF group had a higher fertilization rate [84% vs. 78%, <i>p</i> < 0.05], two-pronucleus (2PN) rate [67% vs. 60%, <i>p</i> < 0.05], and one-pronucleus (1PN) rate [5% vs. 3%, <i>p</i> < 0.05] compared with the S-IVF group. Furthermore, in the C-IVF group, the zero-pronucleus (0PN) rate was lower than in the S-IVF group (11% vs. 20%, mean difference -9 percentage points, 95% CI -12.5 to -5.5, <i>p</i> < 0.001). The good-quality blastocyst rate was numerically higher in the C-IVF group than in the S-IVF group, but the difference was not statistically significant. There was no significant difference in pregnancy rate or abortion rate in cohort between the two groups (early abortion rate among clinical pregnancies: 15.1% [14/93] in C-IVF versus 13.0% [3/23] in S-IVF, <i>p</i> = 1.000). In conclusion, C-IVF had a higher fertilization rate, 2PN rate, and 1PN rate but a lower 0PN rate compared with S-IVF, while there was no difference in embryo development and clinical outcomes.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1801741"},"PeriodicalIF":5.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of a history of type 2 diabetes with short-term mortality in patients with decompensated cirrhosis.","authors":"Honglei Ju, Guixiang Wang, Yujie Zhang, Bo Sun, Chiyi He, Jin Cheng, Wei Wang","doi":"10.3389/fendo.2026.1971737","DOIUrl":"10.3389/fendo.2026.1971737","url":null,"abstract":"<p><strong>Background: </strong>The association between type 2 diabetes mellitus (T2DM) and mortality in patients with liver cirrhosis remains controversial. This study aimed to evaluate whether a history of T2DM influences short-term all-cause mortality in hospitalized patients with decompensated liver cirrhosis (DLC).</p><p><strong>Methods: </strong>We conducted a retrospective study of hospitalized patients with DLC at three medical centers in China between November 2019 and June 2024. The study endpoint was the 6-month mortality. The association between T2DM and mortality was assessed using multivariable logistic regression, and stabilized inverse probability of treatment weighting (sIPTW) analysis was applied for sensitivity analysis.</p><p><strong>Results: </strong>Among 984 eligible patients, 239 (24.3%) had a history of T2DM. Patients with T2DM were older and had a higher prevalence of hypertension and coronary artery disease; however, no significant difference in 6-month mortality was observed between patients with and without T2DM. Multivariable logistic regression showed no independent association between a history of T2DM and mortality (OR = 0.80, 95% CI: 0.51-1.23), this result remained consistent using sIPTW analysis (OR = 0.78, 95% CI: 0.51-1.21).</p><p><strong>Conclusions: </strong>A history of T2DM may not be independently associated with short-term mortality in patients with DLC. These findings suggest that T2DM status may not be prioritized over liver-specific prognostic factors when assessing the short-term mortality risk in patients with DLC.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1971737"},"PeriodicalIF":5.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A proposed psychometabolic endotype of polyendocrine metabolic ovarian syndrome: bidirectional interplay between psychological distress, eating dysfunction, sleep disruption, chronic stress, and metabolic deterioration.","authors":"Hongtao Li, Tong Yin, Yichen Wang, Yixuan Wang, Nenggui Xu, Wei Yi, Han Yang","doi":"10.3389/fendo.2026.1978249","DOIUrl":"10.3389/fendo.2026.1978249","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome (PMOS) in 2026 to better represent its multisystem biology. Psychological distress, eating dysregulation, sleep disturbance, and metabolic dysfunction frequently coexist, yet clinical care and research commonly treat them as parallel comorbidities.</p><p><strong>Objective: </strong>To define the proposed psychometabolic construct operationally; position it relative to conventional phenotypes and data-driven clusters; and grade evidence for association, temporal prediction, causation, and treatment response across psychological, behavioral, sleep-stress, neuroendocrine, and metabolic pathways.</p><p><strong>Methods: </strong>We conducted a targeted narrative review of PubMed/MEDLINE from inception through 15 September 2026. Seven structured topic blocks returned 1,278 records, 1,009 unique identifiers after PubMed identifier (PMID)-based deduplication, and 1,008 retrievable article records for title/abstract screening. Guidelines, systematic reviews, longitudinal or causal studies, trials, and informative human mechanistic studies were prioritized; general-population and preclinical evidence was used only when its indirectness was explicit.</p><p><strong>Evidence synthesis: </strong>Depression and anxiety, body-image concerns, binge- and bulimia-spectrum symptoms, poor sleep, and obstructive sleep apnea are reported more often in PMOS than in comparison populations, but most estimates are cross-sectional and heterogeneous. One tertiary cohort found that baseline depression and/or anxiety history predicted incident metabolic syndrome over a median seven years (adjusted hazard ratio 1.45, 95% confidence interval 1.02-2.06); this supports prognostic enrichment, not causality. General-population longitudinal and genetic studies support reciprocal depression-metabolic relationships, whereas PMOS-specific causal evidence is inconsistent. Plausible links include insulin-androgen-adipose interactions, neuroactive steroid signaling, ovarian sympathetic input, sleep fragmentation, stress and autonomic regulation, reward-related eating, treatment exposure, stigma, and social context. None validates a discrete endotype.</p><p><strong>Conclusions: </strong>We define a candidate psychometabolic endotype as a cross-cutting, mechanistically coupled pattern that may occur within any conventional PMOS phenotype. Clinical co-occurrence is only an entry profile; endotype status requires replicated longitudinal coupling, incremental prognostic value, interpretable transitions, and preferably treatment-effect heterogeneity. Four overlapping prototypes are working formulations rather than subtypes. A six-step clinical pathway centers shared formulation and nests care-intensity tiers within treatment selection.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1978249"},"PeriodicalIF":5.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13684126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}